Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a proprietary 1:1 glucagon/GLP-1 dual receptor agonist peptide, for the treatment of MASH, AUD, and ALD. The company is pre-commercial and preparing to initiate a Phase 3 trial in MASH.
- Company typePublic
- Founded2005
- HeadquartersGaithersburg, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Altimmune does
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a novel investigational peptide-based therapeutic with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity. The company is advancing pemvidutide across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). MASH is the lead indication, where pemvidutide has received both FDA Breakthrough Therapy Designation and Fast Track Designation, supported by positive Phase 2b IMPACT trial data demonstrating 7.5% weight loss, 23.7% triglyceride reduction, 15.4% total cholesterol reduction, and statistically significant MASH resolution without worsening of fibrosis at 24 weeks. AUD has received Fast Track Designation with Phase 2 RECLAIM topline data expected in Q3 2026, and the Phase 2 RESTORE trial in ALD was initiated in July 2025. The technology differentiates from GLP-1-only therapies through direct liver effects mediated by the glucagon receptor pathway.
Altimmune operates as a single-asset company — all three indications flow from the same pemvidutide molecule — and is currently pre-commercial, with Q4 2025 revenue of just $26,000. The company plans to initiate the Phase 3 PERFORMA trial in MASH in H2 2026 with an estimated program cost of approximately $400 million. The business model is pharmaceutical drug development and commercialization; upon approval, revenue is expected to be generated through specialty pharmacy and healthcare provider distribution channels, with analyst peak revenue estimates of $600 million to $1 billion from approximately 20,000 MASH patients.
The company is publicly traded on NASDAQ (ticker: ALT), headquartered in Gaithersburg, MD with a planned relocation to Morristown, NJ in late 2026. As of April 30, 2026, the company held approximately $535 million in cash following two equity offerings in early 2026 totaling approximately $300 million. The senior leadership team was substantially refreshed in 2025-2026 with appointments from Intercept Pharmaceuticals and Sanofi, including CEO Jerome Durso (former CEO/COO of Intercept), CCO Linda Richardson (former CCO of Intercept and Sanofi GLP-1 franchise leader), and CMO Christophe Arbet-Engels (former CMO at X4 Pharmaceuticals, Neurogastrx, and others). The company operates independently without parent or subsidiary structure, though it has secured up to $100 million in debt financing from Hercules Capital in addition to its equity raises.
Altimmune firmographics
Firmographics- Name
- Altimmune
- Legal name
- Altimmune, Inc.
- Website
- https://altimmune.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a proprietary 1:1 glucagon/GLP-1 dual receptor agonist peptide, for the treatment of MASH, AUD, and ALD. The company is pre-commercial and preparing to initiate a Phase 3 trial in MASH.
- Ownership category
- akta.pro rank
Altimmune industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
- akta.pro secondary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
Keywords
Where Altimmune is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Altimmune business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical Drug Development and Commercialization: Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide for liver diseases. Once approved, the company plans to commercialize the drug for MASH, AUD, and ALD indications. Analysts estimate peak revenue potential of $600 million to $1 billion from approximately 20,000 patients.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Altimmune product offering
Product offeringCore offering
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a novel investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity, for the treatment of serious liver diseases. The lead candidate is being advanced across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
Product overview
Altimmune is a late clinical-stage biopharmaceutical company developing a single lead candidate, pemvidutide, a novel peptide-based therapeutic with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity. The company is advancing this one product across three therapeutic indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company does not offer multiple distinct products or modules—all programs flow from the same core pemvidutide molecule with different therapeutic applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Pemvidutide
- Pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Pemvidutide for Alcohol Use Disorder (AUD)
- Pemvidutide for Alcohol-Associated Liver Disease (ALD)
Quantifiable outcome
- 7.5% weight loss at 1.8 mg dose vs 0.2% for placebo in 48-week MASH trial
- +5 more outcomes
Companies that use Altimmune
Customer profileSegments3 records
Ideal customer profiles2 records
Altimmune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Altimmune partnerships and signals
Strategic signalScale indicators11 records
Recent moves8 records
Expansion highlights6 records
Altimmune competitors and assessment
Company assessmentDirect peers
- Madrigal Pharmaceuticals: Late-stage MASH-focused biopharmaceutical company with the first FDA-approved MASH therapy (Rezdiffra/resmetirom). Most direct comparable to Altimmune given similar therapeutic focus, late-stage clinical positioning, and target patient population in MASH.
- Akero Therapeutics: Clinical-stage biotechnology company developing efruxifermin (FGF21 analog) for MASH. Directly comparable to Altimmune in therapeutic area, stage of development, and target patient population, with overlapping metabolic mechanism.
- 89bio: Clinical-stage biopharmaceutical company developing pegozafermin (FGF21 analog) for MASH. Closely comparable to Altimmune given similar therapeutic indication, similar late-Phase-stage profile, and similar company size and focus.
- Viking Therapeutics: Clinical-stage biopharmaceutical company developing dual GLP-1/GIP receptor agonist VK2735 for obesity and related metabolic diseases. Directly comparable mechanism family to pemvidutide and similar late-stage clinical positioning.
- Inventiva: Clinical-stage biopharmaceutical company developing lanifibranor (pan-PPAR agonist) for MASH. Direct comparable in therapeutic area, clinical stage, and target indication.
Emerging players
- Terns Pharmaceuticals: Clinical-stage biopharmaceutical company developing TERN-501 (THR-β agonist) and other candidates for MASH and obesity. Comparable MASH focus with smaller-stage and earlier clinical position than Altimmune.
- Sagimet Biosciences: Clinical-stage biopharmaceutical company developing denifanstat (FASN inhibitor) for MASH. Comparable MASH focus and mechanism-based differentiation play, with similar clinical-stage positioning.
Broad incumbents
- Boehringer Ingelheim / Zealand Pharma: Large-cap incumbents developing survodutide (a dual GLP-1/glucagon agonist) for MASH and obesity. Mechanistically closest direct competitor to pemvidutide, but backed by substantially larger commercial and R&D resources.
- Eli Lilly: Global pharmaceutical incumbent advancing tirzepatide (GLP-1/GIP dual agonist) and retatrutide (GLP-1/GIP/glucagon triple agonist) into MASH and broader metabolic indications. Represents significant competitive pressure with vastly larger commercial footprint than Altimmune.
- Novo Nordisk: Global GLP-1 leader advancing semaglutide (Wegovy) into MASH (ESSENCE trial). Dominant incumbent in the GLP-1 class with established hepatology and metabolic disease commercial infrastructure, representing the largest competitive threat to pemvidutide's market opportunity.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Altimmune social profiles
Digital presenceAltimmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
Altimmune leadership team
Management profileNumber of profiles
Profiles11 records
Altimmune funding detail
Funding detailFunding overview
Funding rounds7 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Altimmune M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Altimmune
What does Altimmune do?
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a novel investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity, for the treatment of serious liver diseases. The lead candidate is being advanced across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
Is Altimmune a public or private company?
Altimmune is a public company. It is classified as public and is currently operating.
When was Altimmune founded?
Altimmune was founded in 2005. It employs 51 to 100 people.
Where is Altimmune based?
Altimmune is headquartered in Gaithersburg, United States, in the North America region.
How does Altimmune make money?
One revenue line is on record: pharmaceutical Drug Development and Commercialization.
Who are Altimmune's main competitors?
Direct peers on record are Madrigal Pharmaceuticals, Akero Therapeutics, 89bio, Viking Therapeutics and Inventiva. Emerging players are Terns Pharmaceuticals and Sagimet Biosciences. Broad incumbents are Boehringer Ingelheim / Zealand Pharma, Eli Lilly and Novo Nordisk.
Does Altimmune have an API?
No public API is recorded for Altimmune.
What industry is Altimmune in?
Altimmune's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.